The routine sequencing of BRAF (exon 15), NRAS (exon 2), and KIT (exons 9, 11, 13, and 17) for clinical purposes, such as molecular-based targeted therapy, suggests that tailored monitoring of the kinetics of plasma ctDNA could be used in the near future for melanoma patients for whom a mutation is detected. The gene discussed is NRAS; the disease is melanoma.